Sanderling Venture Partners VI LP - Jan 23, 2024 Form 4 Insider Report for CalciMedica, Inc. (CALC)

Role
10%+ Owner
Signature
/s/ Sanderling Venture Partners VI, L.P., By: /s/ Timothy C. Mills, Managing Director of Middleton, McNeil & Mills Associates VI, L.P., its General Partner
Stock symbol
CALC
Transactions as of
Jan 23, 2024
Transactions value $
$2,600,003
Form type
4
Date filed
1/25/2024, 08:00 PM
Previous filing
Oct 10, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CALC Common Stock Purchase $901K +243K +34.6% $3.70 947K Jan 23, 2024 Direct F1
transaction CALC Common Stock Purchase $536K +145K +24.83% $3.70 727K Jan 23, 2024 By Sanderling Venture Partners VI Co-Investment Fund, L.P. F1
transaction CALC Common Stock Purchase $720K +194K +80.8% $3.70 435K Jan 23, 2024 By Sanderling Ventures VII, L.P. F1
transaction CALC Common Stock Purchase $189K +51K +80.71% $3.70 114K Jan 23, 2024 By Sanderling Ventures VII (Canada), L.P. F1
transaction CALC Common Stock Purchase $48.8K +13.2K +91.4% $3.70 27.6K Jan 23, 2024 By Sanderling Ventures VII Annex Fund, L.P. F1
transaction CALC Common Stock Purchase $14.5K +3.92K +22.17% $3.70 21.6K Jan 23, 2024 By Sanderling Ventures Management VI F1
transaction CALC Common Stock Purchase $106K +28.7K +1856.85% $3.70 30.3K Jan 23, 2024 By Sanderling Ventures Management VII F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CALC Warrant Purchase $15.2K +122K $0.13* 122K Jan 23, 2024 Common Stock 122K $5.36 Direct F1, F2
transaction CALC Warrant Purchase $15.2K +122K $0.13* 122K Jan 23, 2024 Common Stock 122K $7.15 Direct F1, F3
transaction CALC Warrant Purchase $9.04K +72.3K $0.13* 72.3K Jan 23, 2024 Common Stock 72.3K $5.36 By Sanderling Venture Partners VI Co-Investment Fund, L.P. F1, F2
transaction CALC Warrant Purchase $9.04K +72.3K $0.13* 72.3K Jan 23, 2024 Common Stock 72.3K $7.15 By Sanderling Venture Partners VI Co-Investment Fund, L.P. F1, F3
transaction CALC Warrant Purchase $12.2K +97.2K $0.13* 97.2K Jan 23, 2024 Common Stock 97.2K $5.36 By Sanderling Ventures VII, L.P. F1, F2
transaction CALC Warrant Purchase $12.2K +97.2K $0.13* 97.2K Jan 23, 2024 Common Stock 97.2K $7.15 By Sanderling Ventures VII, L.P. F1, F3
transaction CALC Warrant Purchase $3.19K +25.5K $0.13* 25.5K Jan 23, 2024 Common Stock 25.5K $5.36 By Sanderling Ventures VII (Canada), L.P. F1, F2
transaction CALC Warrant Purchase $3.19K +25.5K $0.13* 25.5K Jan 23, 2024 Common Stock 25.5K $7.15 By Sanderling Ventures VII (Canada), L.P. F1, F3
transaction CALC Warrant Purchase $824 +6.59K $0.13* 6.59K Jan 23, 2024 Common Stock 6.59K $5.36 By Sanderling Ventures VII Annex Fund, L.P. F1, F2
transaction CALC Warrant Purchase $824 +6.59K $0.13* 6.59K Jan 23, 2024 Common Stock 6.59K $7.15 By Sanderling Ventures VII Annex Fund, L.P. F1, F3
transaction CALC Warrant Purchase $245 +1.96K $0.13* 1.96K Jan 23, 2024 Common Stock 1.96K $5.36 By Sanderling Ventures Management VI F1, F2
transaction CALC Warrant Purchase $245 +1.96K $0.13* 1.96K Jan 23, 2024 Common Stock 1.96K $7.15 By Sanderling Ventures Management VI F1, F3
transaction CALC Warrant Purchase $1.8K +14.4K $0.13* 14.4K Jan 23, 2024 Common Stock 14.4K $5.36 By Sanderling Ventures Management VII F1, F2
transaction CALC Warrant Purchase $1.8K +14.4K $0.13* 14.4K Jan 23, 2024 Common Stock 14.4K $7.15 By Sanderling Ventures Management VII F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.
F2 The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.
F3 The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.